# Deepull Diagnostics S.L.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/deepull-diagnostics-s-l

- Industry: Medical Devices & Equipment
- Headquarters: Barcelona, Spain
- Website: www.deepull.com
- Total disclosed funding: $76M
- Latest round: Series C (Apr 9, 2025)
- Investors on record: 14

## About

Based in Spain, Deepull Diagnostics S.L. specializes in developing innovative diagnostic technologies focused on the early detection and management of sepsis, ultimately enhancing patient care and treatment outcomes.Deepull Diagnostics S.L. is a Barcelona-based company founded in 2019, dedicated to advancing diagnostic solutions for sepsis. Led by CEO Jordi Carrera, the firm has successfully completed a total of 6 funding deals. The latest funding round, a Series C, occurred on April 29, 2025, raising EUR 50.000 mn, bringing the total amount raised to EUR 50.000 mn. Investors include prominent firms such as Columbus Venture Partners and Merieux Equity Partners.Deepull specializes in advanced diagnostic technologies aimed at improving the early detection and management of sepsis. The flagship product, the UllCORE BSI Test, analyzes 8 mL of whole blood from patients suspected of infection or sepsis, delivering results in approximately one hour. This rapid diagnostic ability supports healthcare providers in making timely treatment decisions in acute care settings. The technology targets hospital laboratories in markets including the United States and Europe, where there is a demand for sensitive diagnostic tools that can enhance patient outcomes.Deepull's revenue model is built on selling its proprietary diagnostic products, mainly the UllCORE BSI Test, to hospitals and healthcare institutions. Sales typically occur directly to medical facilities, enabling use in emergency departments and microbiology laboratories. The company fosters partnerships with healthcare providers for the integration of diagnostic systems, which may include subscription models for necessary consumables or reagents, with pricing tailored to institutional contracts.In April 2025, Deepull Diagnostics S.L. raised EUR 50.000 mn in Series C funding, aimed at supporting the clinical validation and regulatory approval of their diagnostic system. The company plans to expand its product offerings and explore new geographic markets, focusing on regions that demonstrate a growing need for sepsis diagnostics. Specific details on upcoming product launches are yet to be disclosed.

## Funding rounds

- Series C, Apr 9, 2025, $55M — UI Investissement, Kurma Partners, Merieux Equity Partners, AXIS Participaciones, Panakes Partners, Columbus Venture Partners, Asabys Partners, Center for Technological & Industrial Development, Aliath Bioventures, We Venture Capital, Gesamo
- Series B, Feb 28, 2023, $4.3M — UI Investissement, Kurma Partners, AXIS Participaciones, Werfen Life Group, S.A, Asabys Partners, Alta Life Sciences
- Series B, Oct 15, 2022, $13M — UI Investissement, Kurma Partners, AXIS Participaciones, Werfen Life Group, S.A, Alta Life Sciences, Center for Technological & Industrial Development
- Series A, Jul 7, 2020, $4M — Sofimac Innovation, Kurma Partners, AXIS Participaciones, Alta Life Sciences

## Investors

- Sofimac Innovation (https://capitalatlas.ai/funds/sofimac-innovation) — Series A
- Kurma Partners (https://capitalatlas.ai/funds/kurma-partners) — Series A, Series B, Series C
- AXIS Participaciones (https://capitalatlas.ai/funds/axis-participaciones) — Series A, Series B, Series C
- Alta Life Sciences — Series A, Series B
- UI Investissement (https://capitalatlas.ai/funds/ui-investissement) — Series B, Series C
- Werfen Life Group, S.A — Series B
- Center for Technological & Industrial Development (https://capitalatlas.ai/funds/center-for-technological-industrial-development) — Series B, Series C
- Asabys Partners (https://capitalatlas.ai/funds/asabys-partners) — Series B, Series C
- Merieux Equity Partners (https://capitalatlas.ai/funds/merieux-equity-partners) — Series C
- Panakes Partners (https://capitalatlas.ai/funds/panakes-partners) — Series C
- Columbus Venture Partners (https://capitalatlas.ai/funds/columbus-venture-partners) — Series C
- Aliath Bioventures — Series C
- We Venture Capital (https://capitalatlas.ai/funds/we-venture-capital) — Series C
- Gesamo — Series C